Washington University School of Medicine

Digital Commons@Becker

2006

The intensive care unit as a research laboratory: Developing strategies to prevent antimicrobial resistance

Marin H. Kollef
Washington University School of Medicine in St. Louis

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Surgical Infection Society
Twenty-Fifth Annual Altemeier Lecture

The Intensive Care Unit as a Research Laboratory: Developing Strategies to Prevent Antimicrobial Resistance

MARIN H. KOLLEF

ABSTRACT

Objective: To assemble the available clinical data on the prevention of antimicrobial resistance in the intensive care unit (ICU) setting.

Data Source: A MEDLINE database search and references from identified articles were employed to obtain the literature relating to the prevention of antimicrobial resistance in the ICU.

Conclusions: The ICU presents a unique environment for the conduct of clinical research. The closed physical space with centralized patient management and efficient data recovery allows important clinical questions to be evaluated in a timely manner. Antimicrobial resistance has emerged as an important determinant of mortality for patients in the ICU. Additionally, there is currently a limited pipeline of new agents for the treatment of emerging bacteria with new resistance genes that pose an increasing threat to the ICU patient. Effective strategies for the prevention of antimicrobial resistance within ICUs are available and should be implemented aggressively. These strategies can be divided into non-pharmacologic infection-control strategies (e.g., routine hand hygiene, infection-specific prevention protocols) and antibiotic management strategies (e.g., shorter courses of appropriate antibiotics, narrowing of the antimicrobial spectrum on the basis of culture results). Additional studies conducted in ICUs are needed urgently to identify the optimal approaches for the management of antibiotics in order to balance the need for efficacy with the ability to minimize resistance.

ANTIMICROBIAL RESISTANCE HAS EMERGED as an important issue influencing patient mortality and overall resource utilization in the intensive care unit (ICU) setting [1–3]. Intensive care units worldwide are faced with increasingly rapid emergence and spread of antibiotic-resistant bacteria. Both gram-negative and gram-positive bacteria resistant to antibiotics are reported as important causes of hospital-acquired infections [4–12]. In many circumstances, particularly with methicillin-resistant *Staphylococcus aureus* (MRSA), *Enterococcus faecium*, and gram-negative bacteria producing extended-spectrum beta-lactamase (ESBL) enzymes with resistance to multiple other antibiotics, few agents remain for effective treatment [13–20].

Intensive care units are an important area for the emergence of antimicrobial resistance be-

Pulmonary and Critical Care Division, Washington University School of Medicine, Barnes Jewish Hospital, St. Louis, Missouri.

cause of the frequent use of broad-spectrum antibiotics, the crowding of patients with high levels of disease acuity within relatively small specialized areas, reductions in nursing and other support staff because of economic pressures (increasing the likelihood of person-to-person transmission of microorganisms), and the presence of more chronically and acutely ill patients who require prolonged hospitalization and often harbor antibiotic-resistant bacteria [2,21,22]. Therefore, it makes sense to employ the ICU as a model for the conduct of clinical research aimed at curbing or at least minimizing this problem. Many of the strategies described below have been developed in the ICU setting but also are applicable in other areas of the hospital. In general, these interventions simply attempt to balance the somewhat-competing goals of providing appropriate antimicrobial treatment to critically ill patients while avoiding the unnecessary administration of antibiotics. It is this balance that needs to drive future clinical research in the area of resistance. The strategies described in this review adhere to the Centers for Disease Control and Prevention 12-step program for the prevention of antimicrobial resistance (http://www.cdc.gov/drugresistance/healthcare). One of the key elements in this strategy is to consult experts in the field of antimicrobial resistance (e.g., infectious disease experts, infection control practitioners, microbiologists) when designing interventions aimed at minimizing the emergence of antimicrobial resistance.

ANTIBIOTIC EXPOSURE IS THE MAIN RISK FACTOR FOR ANTIMICROBIAL RESISTANCE

A number of investigators have demonstrated a close association between the use of antibiotics and the emergence of subsequent antibiotic resistance in both gram-negative and gram-positive bacteria [23–33]. Therefore, strategies aimed at limiting or modifying the administration of antimicrobial agents have the greatest likelihood of preventing resistance to these agents. Other factors promoting antimicrobial resistance include prolonged hospitalization; the presence of invasive devices such as endotracheal tubes and intravascular catheters, possibly because of the formation of biofilms on their surfaces; residence in long-term treatment facilities; and inadequate infection control practices [22]. The emergence of new strains of existing pathogens within the community has created additional stressors favoring the entry of resistant microorganisms into the ICU. This has been demonstrated most recently by the identification and spread of community-associated methicillin-resistant *S. aureus* (CA-MRSA) [34,35]. However, prolonged regimens of antimicrobial agents appear to be the most important factor promoting the emergence of antibiotic resistance, one that is potentially amenable to intervention [36,37].

ANTIBIOTIC RESISTANCE AS A DETERMINANT OF HOSPITAL MORTALITY AND HIGHER HEALTH CARE COSTS

Antimicrobial regimens lacking activity against identified microorganisms causing serious infections (i.e., inappropriate antimicrobial therapy) are associated with greater hospital mortality [38–47]. More recently, the same finding has been demonstrated for patients with severe sepsis [48–51]. Unfortunately, changing antimicrobial therapy to an appropriate regimen after susceptibility data become available does not improve clinical outcomes [40,44,46]. These studies suggest that escalating resistance has led to greater overall hospital mortality, in part through the administration of less effective antimicrobial agents. The recent Infectious Diseases Society of America/American Thoracic Society (IDSA/ATS) guidelines for the treatment of ventilator-associated pneumonia (VAP) emphasize the importance of inappropriate antimicrobial therapy as a determinant of hospital mortality [52]. These guidelines also stress the importance of maintaining local, frequently updated antibiograms within individual hospitals and ICUs to ensure the appropriateness of antibiotic coverage and the use of proper drug doses to optimize the tissue concentrations of antibiotics.

In addition to increased hospital mortality, antimicrobial resistance is associated with excess costs. Most of this cost is associated with the acquisition of nosocomial infections, many of which are potentially caused by antibiotic-resistant bacteria [33,53]. However, resistance may actually confer added morbidity and costs as well. For example, MRSA infections are associated with worse clinical outcomes than those attributable to methicillin-sensitive *S. aureus* (MSSA). Cosgrove et al., in a meta-analysis of 30 investigations focusing on bacteremia, concluded that MRSA bacteremia independently increased the risk of death [54]. Similarly, Blot et al. observed that the mortality difference attributable to MRSA relative to MSSA was approximately 25% [55].

All of these efforts have been limited by lack of information about two key confounders: Severity of illness and administration of inappropriate antibiotic therapy. Generally, subjects who develop infections with MRSA are more severely ill, both at admission and at the time of diagnosis, than subjects infected with MSSA. Patients with VAP caused by MRSA also tend to have been hospitalized longer than similar persons with MSSA infection. Most careful investigators have attempted to control for confounding by severity. We recently conducted a retrospective analysis of a large cohort of subjects with bronchoscopically confirmed VAP caused by *S. aureus*, which suggested that MRSA infection has important effects on ICU length of stay and healthcare costs [56]. That is, independent of major contributors to ICU length of stay, such as severity of illness, duration of mechanical ventilation, and administration of appropriate antibiotic therapy, MRSA increased the ICU hospitalization by nearly 50%. Correcting for outliers and for those who consume substantial resources by restricting the analysis to ICU-free days confirmed the disproportionate impact of MRSA on ICU bed use. Assuming conservatively that the cost per day of ICU care equals $2,000 in the U.S., one can compute that each case of MRSA VAP amplified hospital costs by at least $10,000 to $15,000. Therefore, there is an economic motive, along with a clinical efficacy motive, for attempting to minimize the emergence of antibiotic resistance.

WHAT STRATEGIES PREVENT ANTIMICROBIAL RESISTANCE?

Infection control strategies

In general, strategies aimed at the prevention of nosocomial infections caused by antibiotic-resistant bacteria should be employed routinely in all ICUs (Table 1). These interventions can be separated into two broad categories: Specific interventions aimed at the primary prevention of nosocomial infections (e.g., catheter-associated bacteremia, VAP) and the use of infection control practices to prevent horizontal transmission of antibiotic-resistant bacteria.

Hand hygiene and protective barriers

Hand hygiene is still the most important and effective measure to prevent horizontal transmission of antibiotic-resistant nosocomial pathogens [57,58]. Unfortunately, greater patient workloads and decreased staffing have contributed to poor compliance with handwashing and other routine infection control measures, especially in the ICU [59]. Alternative hand hygiene methods using alcohol solutions have been developed that are effective, do not require sinks, can be performed more rapidly than traditional handwashing using soap solutions in order to improve compliance, and are more effective at reducing bacterial colony counts on the hands (60,61). The use of gowns and gloves also reduces horizontal transmission of antibiotic-resistant bacterial pathogens [62,63]. Therefore, appropriate hand disinfection and barrier precautions should be employed to reduce transmission of antibiotic-resistant bacteria in the ICU [64]. The importance of employing routine barrier precautions has been amplified with the emergence of antibiotic-resistant strains of *Clostridium difficile* that possess added virulence attributable both to antibiotic resistance and to the elaboration of a binary toxin [64–66].

The use of hand hygiene, universal gloving, and strict contact precautions appears to be most important in patients colonized or at high risk for colonization with antibiotic-resistant bacteria [67]. Additionally, the use of surveil-

TABLE 1. STRATEGIES TO PREVENT RESISTANCE IN THE ICU

P: Prophylactic administration of antibiotics should be discouraged unless clinically indicated in high-risk patients.

R: Routine appropriate (i.e., active against the identified pathogen) and adequate (e.g., optimal dosing, duration of therapy) treatment of infections.

E: Encourage avoidance of unnecessary use of antimicrobial agents (e.g., empiric antibiotics in the absence of clinical and microbiologic data supporting the presence of infection).

V: Ventilator-associated pneumonia and other specific infection prevention and treatment protocols should be establisned for the local ICU.

E: Employ antiseptic techniques for all invasive procedures.

N: Noncompliance with local infection prevention and antibiotic treatment protocols should not be tolerated.

T: Try always to de-escalate to more narrow-spectrum antibiotic regimens on the basis of culture results and antimicrobial susceptibility data.

R: Restricted formulary control for specific antimicrobial agents or drug classes if there are outbreaks of antibiotic-resistant bacteria.

E: Evade antimicrobial homogeneity. Promote appropriate use of multiple drug classes (e.g., avoid highly restricted antibiotic formularies; consider use of antimicrobial mixing).

S: Strict isolation precautions for patients at high risk for (e.g., patients transferred from long-term care facilities) or found to have infection/colonization with clinically important antibiotic-resistant bacteria.

I: Infectious disease consultation for difficult-to-manage antibiotic-resistant infections and infection control problems.

S: Systematic disinfection of commonly used instruments, devices, patient care materials, and rooms between uses.

T: Teach infection control procedures and optimal antibiotic utilization practices to all staff participating in the care of ICU patients.

A: Active culture surveillance programs to identify patients infected/colonized with clinically important antibiotic-resistant bacteria.

N: Narrow-spectrum antibiotics should be used when appropriate on the basis of microbiology data.

C: Cease appropriate antibiotics for bacterial infections 24 to 48 hours after achieving an appropriate clinical response.

E: Embrace locally developed antibiotic guidelines and protocols aimed at balancing antimicrobial efficacy and preventing the emergence of resistance.

lance cultures to identify patients colonized with antibiotic-resistant bacteria, allowing them to be placed in isolation in an efficient manner, may help to reduce the spread of resistant bacteria [63,68]. Nevertheless, controversy exists over the optimal use of strict isolation precautions typically employing sterile gloves, gowns, and more aggressive surveillance practices to prevent the spread of resistant microbes [69,70]. One potential concern about these techniques is that they may pose a safety issue if health care workers have less contact with critically ill patients [71]. However, the threat and consequences of horizontal cross-infection with antibiotic-resistant bacteria probably outweigh the potential risks of isolation practices in the ICU setting.

Surveillance to detect antimicrobial resistance

Antimicrobial surveillance appears to be a reasonable strategy for detecting the presence of antibiotic-resistant organisms. This may allow the application of both appropriate contact precautions and the prescription of appropriate antimicrobial treatment. Michel et al. recently evaluated twice-weekly quantitative surveillance cultures of endotracheal aspirates in all intubated patients who were receiving mechanical ventilation to assist in the choice

of antibiotic when VAP was suspected [72]. In 34 of 41 cases (83%), pre-VAP endotracheal aspirate cultures identified the same pathogens with similar antibiotic susceptibility patterns as cultures of bronchoalveolar lavage (BAL) fluid obtained when VAP was suspected, and the antibiotic selected on the basis of the results of endotracheal aspirate cultures was appropriate in 38 patients (95%). In contrast, had the original ATS Guidelines [73] or those of Trouillet et al. [33] been followed, the empiric antibiotic treatment would have been appropriate in only 68% and 83% of the patients, respectively. The main reason for the inappropriate coverage using the published guidelines was the failure to treat highly resistant pathogens. In addition to the better coverage, antibiotic selection on the basis of pre-VAP endotracheal aspirate cultures reduced the unnecessary use of some antibiotics, such as the β-lactam agents, compared with strategies based on the original ATS and Trouillet guidelines [33,73]. The results of this study suggest that twice-weekly quantitative surveillance cultures of endotracheal aspirates will assist in the early prescription of appropriate antibiotic treatments for patients who develop VAP. This strategy may improve clinical outcomes, reduce antibiotic resistance within ICUs, and lower hospitalization costs.

Infection-specific protocols and guidelines

Several focused clinical efforts have demonstrated the potential for practice guidelines or protocols promoting sound clinical practices to reduce the rates of VAP [74–79]. Similarly, prevention programs have reduced the occurrence of nosocomial bacteremia by achieving higher rates of compliance with basic prevention practices [80–84]. These protocols and guidelines apply well-accepted practices for infection-specific prevention (e.g., use of sterile gowns/masks/gloves and full drapes during catheter insertion to prevent catheter-associated bacteremia; drainage of ventilator circuit condensate) that are promoted in mandatory education programs. The success of such interventions depends on the degree to which they are accepted by the local ICU community and overall compliance with their implementation [85,86].

Reducing ICU length of stay

The duration of ICU stay and of mechanical ventilation are important risk factors for the development of infections caused by antibiotic-resistant bacteria [33,87]. Therefore, efforts aimed at reducing the duration of hospitalization or exposure to high-risk environments such as the ICU could also reduce the occurrence of infections or colonization attributable to antibiotic-resistant pathogens. Noninvasive mechanical ventilation is one accepted approach to minimizing the duration of hospitalization secondary to respiratory failure; its use has been associated with a lower risk of nosocomial infection [88–90].

Avoidance of the biofilm burden

Biofilms form on surfaces such as endotracheal tubes or urinary catheters when they are encountered by bacteria that settle on them and upregulate genes involved in matrix production [91]. The colonies of bacteria forming the biofilm and detaching from it are under the control of chemical signals of the same type that regulate quorum sensing, and these regulatory molecules guide the formation of the slime-enclosed microcolonies and water channels that make up the biofilm. Certain bacteria, such as *Pseudomonas* species, appear to be more capable of forming biofilms [92]. Biofilms appear to promote the emergence of antibiotic resistance by limiting the access of antibiotics to the bacteria and by inducing the production of chemicals promoting antibiotic resistance [93]. Currently, biofilm prevention technology has been applied only to urinary catheters and central venous catheters.

In general, invasive devices such as central venous catheters should be removed as soon as clinically indicated, as they promote the emergence of infections with antibiotic-resistant bacteria. However, for individuals who cannot be managed without these devices, antimicrobial-coated intravascular and urinary catheters have been associated with reductions in nosocomial infection rates [94–96]. Interestingly, a

recent in vitro study found that subinhibitory concentrations of aminoglycoside antibiotics induce biofilm formation by *Pseudomonas aeruginosa* and *Escherichia coli* [97]. In *P. aeruginosa*, a gene, designated "aminoglycoside response regulator" (*arr*), is essential for this induction and contributes to biofilm-specific aminoglycoside resistance. Therefore, it appears that the degree of antibiotic penetration into a tissue compartment such as the lung can determine whether antibiotic resistance emerges. This finding has been the impetus for the evaluation of aerosolized aminoglycosides as an adjunct for the treatment of gram-negative bacterial pneumonia.

Vaccines

Vaccines for the prevention of antibiotic-resistant bacterial infections are not currently available for clinical use in the ICU setting. However, conjugate vaccine-induced antibodies to *S. aureus* have been demonstrated to reduce blood-stream infection with this pathogen among patients requiring chronic hemodialysis [98]. Investigation of this vaccine among potential ICU patient populations is ongoing [99]. More importantly, the threat of pandemic avian influenza not only carries the risk of a large proportion of the population succumbing to this disease but the threat of greater antibiotic resistance secondary to the likely widespread empiric use of antibiotics during the flu outbreak. This risk has resulted in international efforts to develop a vaccine against this important threat [100].

ANTIBIOTIC MANAGEMENT STRATEGIES

Formal protocols and guidelines

Antibiotic practice guidelines or protocols have emerged as a potentially effective means of both avoiding unnecessary antibiotic administration and increasing the effectiveness of prescribed antibiotics (Fig. 1). Automated antimicrobial utilization guidelines have been successful in identifying and minimizing the occurrence of adverse effects secondary to antibiotic administration and to better antibiotic selection [101,102]. Their use has also been associated with stable antibiotic susceptibility patterns for both gram-positive and gram-negative bacteria, possibly as a result of pro-


FIG. 1. Antimicrobial treatment algorithm aimed at providing appropriate initial treatment to patients while monitoring clinical response along with microbiologic data to facilitate antimicrobial de-escalation (e.g., more narrow-spectrum regimen, shortest course of therapy according to individual patient clinical response).

moting antimicrobial heterogeneity and specific endpoints for antibiotic discontinuation [103,104]. Automated and nonautomated antimicrobial guidelines have also been employed to reduce the overall use of antibiotics and to limit the use of inappropriate antimicrobial treatment, both of which could impact the development of antibiotic resistance [41,105,106]. One way these guidelines limit the unnecessary use of antimicrobial agents is by recommending that initial prescriptions for empiric broad-spectrum antibiotics be modified when the culture results reveal that narrow-spectrum antibiotics can be employed instead [106]. This practice is described as "antimicrobial de-escalation." Unfortunately, clinicians appear to be reluctant to de-escalate despite the emerging evidence in favor of this concept [107].

Hospital formulary restrictions

Restricted use of specific antibiotics or antibiotic classes from the hospital formulary has been employed to reduce the occurrence of antibiotic resistance as well as drug acquisition costs [22]. Although such an approach can achieve reductions in pharmacy expenses and adverse reactions attributable to the restricted drugs [108], not all experiences have been successful; indeed, some have been associated with higher overall antibiotic costs [109]. Restricted use of specific antibiotics has generally been applied to those with a broad spectrum of action (e.g., carbapenems), rapid emergence of antibiotic resistance (e.g., cephalosporins), and readily identified toxicity (e.g., aminoglycosides). To date, it has been difficult to demonstrate that restricted hospital formularies are effective in curbing the overall emergence of antibiotic resistance. This may be secondary in large part to methodologic problems. However, their use has been successful in specific outbreaks of infection with antibiotic-resistant bacteria, particularly in conjunction with infection control practices and antibiotic educational activities [30,110,111]. It is important to note that implementation of this type of intervention will be successful only if such outbreaks are recognized. This requires a systematic approach to patient surveillance for the detection

of potentially antibiotic-resistant bacteria and a microbiology laboratory that can detect the presence of resistance. The latter is not always a simple matter, especially for the detection of gram-negative bacteria possessing ESBL enzymes [30,31].

Use of narrow-spectrum antibiotics

Another proposed strategy to curtail the development of antimicrobial resistance, in addition to the judicious overall use of antibiotics, is to use drugs with a narrow antimicrobial spectrum. Several investigations have suggested that infections such as community-acquired pneumonia can usually be treated successfully with narrow-spectrum agents, especially if the infections are not life threatening [112, 113]. Similarly, avoidance of broad-spectrum antibiotics (e.g., cephalosporins) and reintroduction of narrow-spectrum agents (e.g., penicillin, trimethoprim, gentamicin) along with infection control practices have reduced the occurrence of *C. difficile* infections [114]. Unfortunately, ICU patients often have already received antimicrobial treatment, making it more likely that they will be infected with an antibiotic-resistant pathogen [33]. Additionally, pathogens in the community have changed with the advent of more antibiotic-resistant bacteria such as MRSA and the increasing presence of risk factors for health care-acquired infections [115]. Therefore, initial empiric treatment with broad-spectrum agents is often necessary for ICU patients to avoid inappropriate treatment until culture results become available [42,43].

Quantitative cultures and assessment of infection risk

Pneumonia is the most common hospital-acquired infection among mechanically ventilated patients [3,116]. Unfortunately, establishing a definite diagnosis is difficult because of the nonspecific signs and symptoms associated with this infection. This, in turn, has resulted in largely empiric treatment for VAP. A recent meta-analysis of four randomized trials demonstrated that quantitative bacterial cultures of material obtained from the lower respiratory tract may facilitate de-escalation of empiric broad-spectrum antibiotics and reduce drug-

specific days of treatment [117]. Another recent study found that patients with a clinical suspicion of VAP and culture-negative BAL results for a major pathogen could safely have antimicrobial therapy discontinued within 72 h [118]. Interestingly, the mean modified clinical pulmonary infection score of these patients was approximately six, suggesting that this quantitative clinical assessment of the risk for VAP could have been employed to discontinue antibiotics [119].

Combination antibiotic therapy

Several recent meta-analyses recommend the use of monotherapy with a beta-lactam antibiotic as opposed to combination therapy including an aminoglycoside for the definitive treatment of neutropenic fever and severe sepsis once antimicrobial susceptibilities are known [120,121]. Additionally, there is no definitive evidence that the emergence of antibiotic resistance is reduced by combination antimicrobial therapy. However, empiric combination therapy directed against high-risk pathogens such as *P. aeruginosa* should be encouraged until the results of antimicrobial susceptibility testing become available. Such an approach to empiric treatment can increase the likelihood of providing appropriate initial antimicrobial therapy with improved outcomes [47]. Patients at high risk for infection with potentially antibiotic-resistant bacteria usually can be identified by the presence of factors such as prior antibiotic exposure and longer hospitalization preceding the onset of nosocomial infection [33].

Antibiotic cycling and scheduled antibiotic changes

The concept of antibiotic class cycling has been suggested as a strategy for reducing the emergence of antimicrobial resistance [122]. In theory, a class of antibiotics or a specific antibiotic drug is withdrawn from use for a defined time and reintroduced later in an attempt to limit bacterial resistance to the cycled antimicrobial agents. This offers the potential for antibiotic classes that possess greater overall activity against the predominant ICU pathogens to be used, resulting in more effective treatment of nosocomial infections. Unfortunately, mathematical modeling suggests that the use of antibiotic cycling will be inferior to mixing of antibiotics as a strategy to reduce the emergence of resistance [123]. Nevertheless, several earlier studies of antimicrobial cycling have found beneficial outcomes in terms of antibiotic resistance, with benefits extending outside the ICU setting [124–127]. Because of methodological limitations, including the introduction of uncontrolled changes in infection control and the lack of appropriate control groups, interpretation of these studies has been difficult.

Two recent studies attempted to minimize the influences of confounding effects in order to evaluate the role of antimicrobial cycling on resistance. Warren et al., employing scheduled surveillance cultures, demonstrated that antimicrobial cycling did not influence the emergence of resistance in an ICU adhering to the principles of antimicrobial de-escalation [128]. Similarly, van Loon et al., who evaluated the impact of antibiotic cycling using rectal and respiratory surveillance cultures and DNA fingerprinting [129], found that overall antibiotic use increased by 24%, with acquisition of resistant bacteria being highest with levofloxacin and pipercillin/tazobactam exposure. Although antimicrobial heterogeneity or mixing seems to be a logical policy, simple cycling of antibiotics combined with prolonged treatment seems only to promote further antibiotic resistance [130].

Antimicrobial decolonization strategies

The prophylactic administration of parenteral antibiotics reduces the occurrence of nosocomial infections in specific high-risk patient populations requiring intensive care [131,132]. Similarly, topical antibiotic administration (i.e., selective digestive decontamination), with or without concomitant parenteral antibiotics, is also effective at reducing nosocomial infections [133–135]. However, the routine use of selective digestive decontamination has been associated with the emergence of antimicrobial resistance [136,137]. Additionally, the results of recent negative trials for VAP prevention employing iseganan and chlorhexidine, an antimicrobial peptide and antiseptic, respectively, to decontaminate the oropharynx in mechanically ventilated patients sheds doubt on the overall

utility of this practice [138,139]. According to these studies, antimicrobial and non-antimicrobial agents should be considered for oral decontamination only in appropriate high-risk ICU patients or to assist in the containment of outbreaks of infections with multi-drug-resistant bacteria in conjunction with established infection control practices [140].

Shorter courses of antibiotic treatment

Prolonged administration of antibiotics to ICU patients is an important risk factor for the emergence of colonization and infection with antibiotic-resistant bacteria [33,37,130]. Therefore, recent attempts have been made to reduce the duration of antibiotic treatment for specific bacterial infections. Several clinical trials have found that seven or eight days of antibiotic treatment is acceptable for most non-bacteremic patients with VAP [36,41,106]. Similarly, shorter courses of antibiotic treatment have been successful in patients at low risk for VAP [106,118,119], with pyelonephritis [141], and with community-acquired pneumonia [142]. In general, the shorter-course regimens have been associated with significantly lower risks of emergence of antimicrobial resistance than the more traditional durations of 14 to 21 days. In the future, more specific markers for the presence of bacterial infection (e.g., sTREM1) may allow shorter courses of empiric antibiotic administration in patients without identified bacterial infection [143,144]. Several recently published guidelines for the antibiotic management of nosocomial pneumonia and severe sepsis recommend the discontinuation of empiric antibiotic therapy after 48–72 h if cultures are negative or the signs of infection have resolved [52,145].

Optimizing pharmacokinetic/pharmocodynamic (PK/PD) principles

Sublethal antibiotic concentrations can promote the emergence of resistant pathogens. Optimization of antibiotic regimens on the basis of pharmacokinetic and pharmacodynamic (PK/PD) principles thus could play a role in the reduction of antibiotic resistance. The time the serum drug concentration remains above the minimum inhibitory concentration (MIC) of the antibiotic ($T > MIC$) enhances bacterial eradication by beta-lactams, carbapenems, monobactams, glycopeptides, and oxazolidinones. Frequent dosing, prolonged infusion times, or continuous infusions can increase the $T > MIC$ and improve clinical and microbiological cure rates [146–150]. In order to maximize the bactericidal effects of aminoglycosides, clinicians must optimize the maximum drug concentration (C_{max}):MIC ratio. A C_{max}: MIC ratio of $\geq 10{:}1$ using once-daily aminoglycoside dosing (5–7 mg/kg) has prevented the emergence of resistant organisms, improved the clinical response to treatment, and avoided toxicity [151–153]. The 24-hour area under the antibiotic concentration curve:MIC ratio (AUIC) is correlated with fluoroquinolone efficacy and prevention of resistance development. An AUIC value >100 has been associated with a significant reduction in the risk of resistance development during therapy [154–155].

CONCLUSION

The ICU should be considered a laboratory for the conduct of important outcomes research. Because of the importance of antimicrobial resistance as a determinant of outcome for critically ill patients, this is a logical location for the investigation of this important clinical problem. Although a lack of federal funding and resources may stand in the way of such research, its importance requires a dedicated group of investigators willing to devote time and career development to this area. Therefore, long-term efforts are required to identify and develop new and dependable sources of funding to enhance this scientific agenda, as well as other important areas of ICU outcomes research.

REFERENCES

1. Goldmann DA, Weinstein RA, Wenzel RP, et al. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals: A challenge to hospital leadership. JAMA 1996;275:234–240.
2. Carlet J, Ben Ali A, Chalfine A. Epidemiology and control of antibiotic resistance in the intensive care unit. Curr Opin Infect Dis 2004;17:309–316.

3. Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe: Results of the European Prevalence of Infection in Intensive Care (EPIC) Study; EPIC International Advisory Committee. JAMA 1995;274:639–644.

4. Waldvogel FA. New resistance in *Staphylococcus aureus*. N Engl J Med 1999;340:556–557.

5. Hanberger H, Garcia-Rodriguez JA, Gobernado M, et al. Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. JAMA 1999;281:67–71.

6. Quinn JP. Clinical problems posed by multiresistant nonfermenting gram-negative pathogens. Clin Infect Dis 1998;27:S117–S124.

7. Jones RN, Sader HS, Beach ML. Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18569 strains non-fermentative gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997–2001). Int J Antimicrob Agents 2003;22:551–556.

8. Livermore DM. Bacterial resistance: Origins, epidemiology, and impact. Clin Infect Dis 2003;36:S11–S23.

9. Dellinger RP, Carlet JM, Masur H, et al, Surviving Sepsis Campaign Management Guidelines Committee. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004;32:858–873.

10. Schlaes DM, Gerding DN, John JF Jr, et al, Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance. Guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997;25:584–599.

11. Neuhauser MM, Weinstein RA, Rydman R, et al. Antibiotic resistance among gram-negative bacilli in US intensive care units: Implications for fluoroquinolone use. JAMA 2003;289:885–888.

12. Archibald L, Phillips L, Monnet D, et al. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: Increasing importance of the intensive care unit. Clin Infect Dis 1997;24:211–215.

13. Sieradzki K, Roberts RB, Haber SW, et al. The development of vancomycin resistance in a patient with methicillin-resistant *Staphylococcus aureus* infection. N Engl J Med 1999;340:517–523.

14. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in *Staphylococcus aureus*. N Engl J Med 1999;340:493–501.

15. Van Looveren M, Goossens H. Antimicrobial resistance of *Acinetobacter spp*. in Europe. Clin Microbiol Infect 2004;10:684–704.

16. Canton R, Coque TM, Baquero F. Multi-resistant gram-negative bacilli: From epidemics to endemics. Curr Opin Infect Dis 2003;16:315–325.

17. Pagani L, Colinon C, Migliavacca R, et al. Nosocomial outbreak caused by multidrug-resistant *Pseudomonas aeruginosa* producing IMP-13 metallo-beta-lactamase. J Clin Microbiol 2005;43:3824–3828.

18. Naiemi NA, Duim B, Savelkoul PH, et al. Widespread transfer of resistance genes between bacterial species in an intensive care unit: Implications for hospital epidemiology. J Clin Microbiol 2005;43:4862–4864.

19. Cartolano GL, Cheron M, Benabid D, et al. Association of Hospital Bacteriologists, Virologists and Hygiene Professionals. Methicillin-resistant *Staphylococcus aureus* (MRSA) with reduced susceptibility to glycopeptides (GISA) in 63 French general hospitals. Clin Microbiol Infect 2004;10:448–451.

20. Jones RN. Microbiological features of vancomycin in the 21st Century: Minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis 2005;42:S13–S24.

21. Haley RW, Bregman DA. The role of understaffing and overcrowding in recurrent outbreaks of staphylococcal infection in a neonatal special-care unit. J Infect Dis 1982;145:875–885.

22. Kollef MH, Fraser VJ. Antibiotic resistance in the intensive care unit. Ann Intern Med 2001;134:298–314.

23. Kollef MH, Micek ST. Strategies to prevent antimicrobial resistance in the intensive care unit. Crit Care Med 2005;33:1845–1853.

24. Zaoutis TE, Goyal M, Chu JH, et al. Risk factors for and outcomes of bloodstream infection caused by extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella* species in children. Pediatrics 2005;115:942–949.

25. del Mar Tomas M, Cartelle M, Pertega S, et al. Hospital outbreak caused by a carbapenem-resistant strain of *Acinetobacter baumannii*: Patient prognosis and risk-factors for colonisation and infection. Clin Microbiol Infect 2005;11:540–546.

26. Husni RN, Goldstein LS, Arroliga AC, et al. Risk factors for an outbreak of multi-drug-resistant *Acinetobacter* nosocomial pneumonia among intubated patients. Chest 1999;115:1378–1382.

27. Rello J, Ausina V, Ricart M, et al. Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia. Chest 1993;104:1230–1235.

28. Kollef MH. Ventilator-associated pneumonia: A multivariate analysis. JAMA 1993;270:1965–1970.

29. Kollef MH, Silver P, Murphy DM, et al. The effect of late-onset ventilator-associated pneumonia in determining patient mortality. Chest 1995;108:1655–1662.

30. Rahal JJ, Urban C, Horn D, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial *Klebsiella*. JAMA 1998;280:1233–1237.

31. Meyer KS, Urban C, Eagan JA, et al. Nosocomial outbreak of *Klebsiella* infection resistant to late-generation cephalosporins. Ann Intern Med 1993;119:353–358.

32. Urban C, Go E, Mariano N, et al. Effect of sulbactam on infections caused by imipenem-resistant *Acinetobacter calcoaceticus* biotype antratus. J Infect Dis 1993;167:448–451.

33. Trouillet JL, Chastre J, Vuagnat A, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998;157:531–539.

34. Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community- and health care-associated methicillin-resistant *Staphylococcus aureus* infection. JAMA 2004;290:2976–2984.

35. Clark NM, Hershberger E, Zervosc MJ, et al. Antimicrobial resistance among gram-positive organisms in the intensive care unit. Curr Opin Crit Care 2003;9:403–412.

36. Chastre J, Wolff M, Fagon JY, et al. Comparison of 15 vs. 8 days of antibiotic therapy for ventilator-associated pneumonia in adults: A randomized trial. JAMA 2003;290:2588–2598.

37. Dennesen PJW, van der Ven AJ, Kessels AGH, et al. Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am J Respir Crit Care Med 2001;163:1371–1375.

38. Ibrahim EH, Sherman G, Ward S, et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000;118:146–155.

39. Harbarth S, Ferriere K, Hugonnet S, et al. Epidemiology and prognostic determinants of bloodstream infections in surgical intensive care. Arch Surg 2002;137:1353–1359.

40. Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. Intens Care Med 1996;22:387–394.

41. Ibrahim EH, Ward S, Sherman G, et al. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 2001;29:1109–1115.

42. Kollef MH. Inadequate antimicrobial treatment: An important determinant of outcome for hospitalized patients. Clin Infect Dis 2000;31:S131–S138.

43. Kollef MH, Sherman G, Ward S, et al. Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients. Chest 1999;115:462–474.

44. Kollef MH, Ward S. The influence of mini-BAL cultures on patient outcomes: Implications for the antibiotic management of ventilator-associated pneumonia. Chest 1998;113:412–420.

45. Rello J, Gallego M, Mariscal D, et al. The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med 1997;156:196–200.

46. Luna CM, Vujacich P, Niederman MS, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997;111:676–685.

47. Micek ST, Lloyd AE, Ritchie DJ, et al. *Pseudomonas aeruginosa* bloodstream infection: Importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005;49:1306–1311.

48. Dhainaut JF, Laterre PF, LaRosa S, et al. The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): Role, methodology, and results. Crit Care Med 2003;31:2291–2301.

49. Harbarth S, Garbino JK, Pugin J, et al. Inappropriate initial antimicrobial therapy and its effects on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003;115:529–535.

50. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, et al. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003;31:2742–2751.

51. Micek ST, Isakow W, Shannon W, et al. Predictors of hospital mortality for patients with severe sepsis treated with drotrecogin alfa (activated). Pharmacotherapy 2005;25:26–34.

52. American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Resp Crit Care Med 2005;171:388–416.

53. Rello J, Ollendorf DA, Oster G, et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002;122:2115–2121.

54. Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible *Staphylococcus aureus* bacteremia: A meta-analysis. Clin Infect Dis 2003;36:53–59.

55. Blot SI, Vandewoude KH, Hoste EA, et al. Outcome and attributable mortality in critically ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant *Staphylococcus aureus*. Arch Intern Med 2002;162:2229–2235.

56. Shorr AF, Combes A, Kollef MH, et al. Methicillin-resistant *Staphylococcus aureus* prolongs intensive care unit length of stay in ventilator-associated pneumonia despite initially appropriate antibiotic therapy. Crit Care Med 2006;34:700–706.

57. Jarvis WR. Handwashing—The Semmelweis lesson forgotten? Lancet 1994;344:1311–1312.

58. Doebbeling BN, Stanley GL, Sheetz CT, et al. Comparative efficacy of alternative hand-washing agents in reducing nosocomial infections in intensive care units. N Engl J Med 1992;327:88–93.

59. Pittet D, Mourouga P, Perneger TV. Compliance with handwashing in a teaching hospital. Ann Intern Med 1999;130:126–130.

60. Zaragoza M, Sallés M, Gomez J, et al. Handwashing with soap or alcoholic solutions? A randomized clinical trial of its effectiveness. Am J Infect Control 1999;27:258–261.

61. Pittet D, Dharan S, Touveneau S, et al. Bacterial contamination of the hands of hospital staff during routine patient care. Arch Intern Med 1999;159:821–826.

62. Slaughter S, Hayden MK, Nathan C, et al. A comparison of the effect of universal use of gloves and gowns with that of glove use alone on acquisition of vancomycin-resistant enterococci in a medical intensive care unit. Ann Intern Med 1996;125:448–456.

63. Puzniak LA, Gillespie KN, Leet T, et al. A cost-benefit analysis of gown use in controlling vancomycin-resistant *Enterococcus* transmission: Is it worth the price? Infect Control Hosp Epidemiol 2004;25:418–424.

64. Loo V, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of *Clostridium difficile*-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442–2449.

65. McDonald LC, Kilgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of *Clostridium difficile*. N Engl J Med 2005;353:2433–2441.

66. Bartlett JG, Perl TM. The new *Clostridium difficile*—What does it mean? N Engl J Med 2005;343:2503–2505.

67. Boyce JM, Pittet D. Guideline for Hand Hygiene in Health-Care Settings: Recommendations of the Healthcare Infection Control Practices Advisory Committee and the ICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. MMWR Recomm Rep 2002;51:1–44.

68. Puzniak LA, Mayfield J, Leet T, et al. Acquisition of vancomycin-resistant enterococci during scheduled antimicrobial rotation in an intensive care unit. Clin Infect Dis 2001;15:151–715.

69. LeDell K, Muto CA, Jarvis WR, et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of *Staphylococcus aureus* and *Enterococcus*. Infect Control Hosp Epidemiol 2003;24:639–641.

70. Sehulster L, Chinn RY, CDC, HICPAC. Guidelines for environmental infection control in health-care facilities: Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 2003;6:1–42.

71. Tarnow-Mordi WO, Hau C, Warden A, et al. Hospital mortality in relation to staff workload: A 4-year study in an adult intensive-care unit. Lancet 2000;356:185–189.

72. Michel F, Franceschini B, Berger P, et al. Early antibiotic treatment for BAL-confirmed ventilator-associated pneumonia: A role for routine endotracheal aspirate cultures. Chest 2005;127:589–597.

73. Campbell, GD, Niederman, MS, Broughton WA, et al. Hospital-acquired pneumonia in adults: Diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies: A consensus statement. Am J Respir Crit Care Med 1996;153:1711–1725.

74. Joiner GA, Salisbury D, Bollin GE. Utilizing quality assurance as a tool for reducing the risk of nosocomial ventilator-associated pneumonia. Am J Med Qual 1996;11:100–103.

75. Kelleghan SI, Salemi C, Padilla S, et al. An effective continuous quality improvement approach to the prevention of ventilator-associated pneumonia. Am J Infect Control 1993;21:322–330.

76. Boyce JM, White RL, Spruill EY, et al. Cost-effective application of the Centers for Disease Control Guideline for Prevention of Nosocomial Pneumonia. Am J Infect Control 1985;13:228–232.

77. Gaynes RP, Solomon S. Improving hospital-acquired infection rates: The CDC experience. Joint Comm J Qual Improv 1996;22:457–467.

78. Zack JE, Garrison T, Trovillion E, et al. Effect of an education program aimed at reducing the occurrence of ventilator-associated pneumonia. Crit Care Med 2002;30:2407–2412.

79. Babcock HM, Zack JE, Garrison T, et al. An education intervention to reduce ventilator-associated pneumonia in an integrated health system: A comparison of effects. Chest 2004;125:2224–2231.

80. Eggimann P, Harbarth S, Constantin MN, et al. Impact of a prevention strategy targeted at vascular-access care on incidence of infections acquired in intensive care. Lancet 2000;355:1864–1868.

81. Bijma R, Girbes AR, Kleijer DJ, et al. Preventing central venous catheter-related infection in a surgical intensive-care unit. Infect Control Hosp Epidemiol 1999;20:618–620.

82. Warren DK, Zack JE, Cox MJ, et al. An educational intervention to prevent catheter-associated bloodstream infections in a nonteaching, community medical center. Crit Care Med 2003;31:1959–1963.

83. Coopersmith CM, Rebmann TL, Zack JE, et al. Effect of an education program on decreasing catheter-related bloodstream infections in the surgical intensive care unit. Crit Care Med 2002;30:59–64.

84. Warren DK, Zack JE, Mayfield JL, et al. The effect of an education program on the incidence of central venous catheter-associated bloodstream infection in a medical ICU. Chest 2004;126:1612–1618.

85. Thoren J-B, Kaelin RM, Jolliet P, et al. Influence of the quality of nursing on the duration of weaning from mechanical ventilation in patients with chronic obstructive pulmonary disease. Crit Care Med 1995;23:1807–1815.

86. Berwick DM. Continuous improvement as an idea in healthcare. N Engl J Med 1989;320:53–56.

87. Kim PW, Harris AD, Roghmann MC, et al. Epidemiological risk factors for isolation of ceftriaxone-resistant versus -susceptible *Citrobacter freundii* in hospitalized patients. Antimicrob Agents Chemother 2003;47:2882–2887.

88. Nava S, Ambrosino N, Clini E, et al. Noninvasive mechanical ventilation in the weaning of patients with respiratory failure due to chronic obstructive pulmonary disease: A randomized, controlled trial. Ann Intern Med 1998;128:721–728.

89. Antonelli M, Conti G, Rocco M, et al. A comparison of noninvasive positive-pressure ventilation and conventional mechanical ventilation in patients with acute respiratory failure. N Engl J Med 1998;339:429–435.

90. Nourdine K, Combes P, Carlton MJ, et al. Does noninvasive ventilation reduce the ICU nosocomial infection risk? A prospective clinical survey. Intens Care Med 1999;25:567–573.

91. Fuqua WC, Greenberg EP. Listening in on bacteria: Acyl-homoserine lactone signaling. Nat Rev Mol Cell Biol 2002;3:685–695.

92. Erwin AL, VanDevanter DR. The *Pseudomonas aeruginosa* genome: How do we use it to develop strategies for the treatment of patients with cystic fibrosis and *Pseudomonas* infections? Curr Opin Pulm Med 2002;8:547–551.

93. Donlan RM, Costerton JW. Biofilms: Survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 2002;15:167–193.

94. Trautner BW, Darouiche RO. Catheter-associated infections: Pathogenesis affects prevention. Arch Intern Med 2004;164:842–850.

95. Saint S, Savel RH, Matthay MA. Enhancing the safety of critically ill patients by reducing urinary and central venous catheter-related infections. Am J Respir Crit Care Med 2002;165:1475–1479.

96. Darouiche RO, Raad II, Heard SO, et al. A comparison of two antimicrobial-impregnated central venous catheters. N Engl J Med 1999;340:1–8.

97. Hoffman LR, D'Argenio DA, MacCoss MJ, et al. Aminoglycoside antibiotics induce bacterial biofilm formation. Nature 2005;436:1171–1175.

98. Shinefield H, Black S, Fattom A, et al. Use of a *Staphylococcus aureus* conjugate vaccine in patients receiving hemodialysis. N Engl J Med 2002;346:491–496.

99. Robbins JB, Schneerson R, Horwith G, et al. *Staphylococcus aureus* types 5 and 8 capsular polysaccharide-protein conjugate vaccines. Am Heart J 2004;147:593–598.

100. Quirk M. Avian influenza vaccine clinical trial begins in USA. Lancet Infect Dis 2005;5:266.

101. Classen DC, Pestotnik SL, Evans RS, et al. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1997;277:301–306.

102. Evans RS, Classen DC, Pestotnik SL, et al. Improving empiric antibiotic selection using computer decision support. Arch Intern Med 1994;154:878–884.

103. Pestotnik SL, Classen DC, Evans RS, et al. Implementing antibiotic practice guidelines through computer-assisted decision support: Clinical and financial outcomes. Ann Intern Med 1996;124:884–890.

104. Evans RS, Pestotnik SL, Classen DC, et al. A computer-assisted management program for antibiotics and other antiinfective agents. N Engl J Med 1998;338:232–238.

105. Bailey TC, Ritchie DJ, McMullin ST, et al. A randomized, prospective evaluation of an interventional program to discontinue intravenous antibiotics at two tertiary care teaching institutions. Pharmacotherapy 1997;17:277–281.

106. Micek ST, Ward S, Fraser VJ, et al. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest 2004;125:1791–1799.

107. Kollef MH, Morrow L, Niederman MS, et al. Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia: Descriptive findings from the Assessment of Local Antimicrobial Resistance Measures (ALARM) Study. Chest (in press).

108. McGowan JE Jr, Gerding DN. Does antibiotic restriction prevent resistance? New Horizons 1996;4:370–376.

109. Rifenburg RP, Paladino JA, Hanson SC, et al. Benchmark analysis of strategies hospitals use to control antimicrobial expenditures. Am J Health-System Pharm 1996;53:2054–2062.

110. Climo MW, Israel DS, Wong ES, et al. Hospital-wide restriction of clindamycin: Effect on the incidence of *Clostridium difficile*-associated diarrhea and cost. Ann Intern Med 1998;128:989–995.

111. Quale J, Landman D, Atwood E, et al. Experience with a hospital-wide outbreak of vancomycin-resistant enterococci. Am J Infect Control 1996;24:372–379.

112. Gleason PP, Kapoor WN, Stone RA, et al. Medical outcomes and antimicrobial costs with the use of the American Thoracic Society Guidelines for outpatients with community-acquired pneumonia. JAMA 1997;278:32–39.

113. Ailani RK, Agastya G, Ailani RK, et al. Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia. Arch Intern Med 1999;159:266–270.

114. McNulty C, Logan M, Donald IP, et al. Successful control of *Clostridium difficile* infection in an elderly care unit through use of a restrictive antibiotic policy. J Antimicrob Chemother 1997;40:707–711.

115. Kollef MH, Shorr A, Tabak YP, et al. Epidemiology and outcomes of healthcare-associated pneumonia: Results from a large US database of culture-positive pneumonia. Chest 2005;128:3854–3862.

116. Richards MJ, Edwards JR, Culver DH, et al. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 1999;27:887–892.

117. Shorr AF, Sherner JH, Jackson WL, et al. Invasive approaches to the diagnosis of ventilator-associated pneumonia: A meta-analysis. Crit Care Med 2005;33:46–53.

118. Kollef MH, Kollef KE. Antibiotic utilization and outcomes for patients with clinically suspected ventilator-associated pneumonia and negative quantitative BAL culture results. Chest 2005;128:2706–2713.

119. Singh N, Rogers P, Atwood CW, et al. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit: A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000;162:505–511.

120. Paul M, Benuri-Silbiger I, Soares-Weiser K, et al. Beta-lactam monotherapy versus beta-lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: Systematic review and meta-analysis of randomized trials. BMJ 2004;328:668.

121. Paul M, Soares-Weiser K, Leibovici L. Beta-lactam monotherapy versus beta-lactam-aminoglycoside combination therapy for fever with neutropenia: Systematic review and meta-analysis. BMJ 2003;326:1111.

122. Niederman MS. Is "crop rotation" of antibiotics the solution to a "resistant" problem in the ICU? Am J Respir Crit Care Med 1997;156:1029–1031.

123. Bergstrom CT, Lo M, Lipsitch M. Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals. Proc Natl Acad Sci USA 2004;101:13285–13290.

124. Gruson D, Hilbert G, Vargas F, et al. Rotation and restricted use of antibiotics in a medical intensive care unit: Impact on the incidence of ventilator-associated pneumonia caused by antibiotic-resistant gram-negative bacteria. Am J Respir Crit Care Med 2000;162:837–843.

125. Gruson D, Hilbert G, Vargas F, et al. Strategy of antibiotic rotation: Long-term effect on incidence and susceptibilities of gram-negative bacilli responsible for ventilator-associated pneumonia. Crit Care Med 2003;31:1908–1914.

126. Raymond DP, Pelletier SJ, Crabtree TD, et al. Impact of a rotating empiric antibiotic schedule on infectious mortality in an intensive care unit. Crit Care Med 2001;29:1101–1108.

127. Hughes MG, Evans L, Chong TW, et al. Effect of an intensive care unit rotating empiric antibiotic schedule on the development of hospital-acquired infection on the non-intensive care unit ward. Crit Care Med 2004;32:53–60.

128. Warren DK, Hill HA, Merz LR, et al. Cycling empirical antimicrobial agents to prevent emergence of antimicrobial-resistant gram-negative bacteria among intensive care unit patients. Crit Care Med 2004; 32:2450–2456.

129. van Loon HJ, Vriens MR, Fluit AC, et al. Antibiotic rotation and development of gram-negative antibiotic resistance. Am J Respir Crit Care Med 2005; 171:480–487.

130. Nseir S, Di Pompeo C, Soubrier S, et al. First-generation fluoroquinolone use and subsequent emergence of multiple drug-resistant bacteria in the intensive care unit. Crit Care Med 2005;33:283–289.

131. Sirvent JM, Torres A, El-Ebiary M, et al. A protective effect of intravenously administered cefuroxime against nosocomial pneumonia in patients with structural coma. Am J Respir Crit Care Med 1997; 155:1729–1734.

132. Classen DC, Evans RS, Pestotnik SL, et al. The timing of prophylactic administration of antibiotics and the risk of surgical wound infection. N Engl J Med 1992;326:281–286.

133. D'Amico R, Pifferi S, Leonetti C, et al. Effectiveness of antibiotic prophylaxis in critically ill adult patients: Systemic review of randomized controlled trials. BMJ 1998;316:1275–1285.

134. Krueger WA, Lenhart FP, Neeser G, et al. Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: A prospective, stratified, randomized, double-blind, placebo-controlled clinical trial. Am J Respir Crit Care Med 2002;166:1029–1037.

135. de Jonge E, Schultz M, Spanjaard L, et al. Effects of selective decontamination of the digestive tract on mortality and acquisition of resistant bacteria in intensive care: A randomized controlled trial. Lancet 2003;362:1011–1016.

136. Gastinne H, Wolff M, Delatour F, et al. A controlled trial in intensive care units of selective decontamination of the digestive tract with nonabsorbable antibiotics. N Engl J Med 1992;326:594–599.

137. Hammond JMJ, Potgieter PD. Long-term effects of selective decontamination on antimicrobial resistance. Crit Care Med 1995;23:637–645.

138. Kollef MH, Pittet D, Sánchez García M, et al. A randomized, double-blind, placebo-controlled, multinational phase III trial of iseganan in prevention of ventilator-associated pneumonia. Am J Respir Crit Care Med (in press).

139. Fourrier F, Dubois D, Pronnier P, et al. Effect of gingival and dental plaque antiseptic decontamination on nosocomial infections acquired in the intensive care unit: A double-blind placebo-controlled multicenter study. Crit Care Med 2005;33:1728–1735.

140. Brun-Buisson C, Legrand P, Rauss A, et al. Intestinal decontamination for control of nosocomial multiresistant gram-negative bacilli: Study of an outbreak in an intensive care unit. Ann Intern Med 1989;110:873–881.

141. Talan DA, Stamm WE, Hooton TM, et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: A randomized trial. JAMA 2000;283:1583–1590.

142. Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: A new treatment paradigm. Clin Infect Dis 2003;37:752–760.

143. Gibot S, Cravoisy A, Levy B, et al. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N Engl J Med 2004;350: 451–458.

144. Gibot S, Kolopp-Sarda MN, Bene MC, et al. Plasma level of a triggering receptor expressed on myeloid cells-1: Its diagnostic accuracy in patients with suspected sepsis. Ann Intern Med 2004;141:9–15.

145. Viviani M, Silvestri L, van Saene HK, et al. Surviving Sepsis Campaign Guidelines: Selective decontamination of the digestive tract still neglected. Crit Care Med 2005;33:462–463.

146. Benko AS, Cappelletty DM, Kruse JA, et al. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections. Antimicrob Agents Chemother 1996;40:691–695.

147. Boselli E, Breilh D, Duflo F, et al. Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe pneumonia. Crit Care Med 2003; 31:2102–2106.

148. Wysocki M, Delatour F, Faurisson F, et al. Continuous versus intermittent infusion of vancomycin in se-

vere staphylococcal infections: Prospective multicenter randomized study. Antimicrob Agents Chemother 2001;45:2460–2467.

149. Lipman J, Wallis SC, Rickard C. Low plasma cefepime levels in critically ill septic patients: Pharmacokinetic modeling indicates improved troughs with revised dosing. Antimicrob Agents Chemother 1999;43:2559–2561.

150. Rello J, Sole-Violan J, Sa-Borges M, et al. Pneumonia caused by oxacillin-resistant *Staphylococcus aureus* treated with glycopeptides. Crit Care Med 2005;33: 1983–1987.

151. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: The importance of peak concentration to minimal inhibitory concentration. J Infect Dis 1987;155:93–99.

152. Blaser J, Stone BB, Groner MC, et al. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine the importance of ratio of peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 1987;31:1054–1060.

153. Verpooten GA, Giuliano RA, Verbist L, et al. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther 1989;45:22–27.

154. Thomas JK, Forrest A, Bhavnani SM, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998;42:521–527.

155. Schentag JJ, Gilliland KK, Paladino JA. What have we learned from pharmacokinetic and pharmacodynamic theories? Clin Infect Dis 2001;32:S39–S46.

Address reprint requests to:
Dr. Marin H. Kollef
Pulmonary and Critical Care Division
Washington University School of Medicine
Barnes Jewish Hospital
Campus Box 8052
660 South Euclid Avenue
St. Louis, MO 63110

E-mail: mkollef@im.wustl.edu